Previous 10 | Next 10 |
Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel ™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on com...
Richland WA, June 10, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced that is has submitted an international application based on its patent submittal last June. This is part of the Patent Cooperation Treaty (PCT), which cover 153 countries. It allows 30 months for th...
Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20. Our East Coast Y-90 supplier, our Texas production site a...
Richland WA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos today announced that the University of Missouri College of Veterinary Medicine will be the first Isopet ® regional clinic. The Isopet ® therapy will now be included as a treatment option within th...
Richland WA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2019 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2020, I think it is important to review our progress during past year and to provide some insight ...
Richland WA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that two dogs with different cancer types were treated using Vivos Inc.’s Isopet ® therapy on November 27 at our pilot clinic, Vista Veterinary Hospital in Kennewick, WA. One dog with ...
Richland WA, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos, Inc. key personnel attended the Veterinary Cancer Society annual meeting last week in Houston Texas which was attended by nearly 700 veterinary oncology professionals. Vivos was a bronze sponsor at this prem...
Richland WA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that its common shares have been approve...
Some investors love penny stocks. It’s clear why; low buy-in prices and the possibility of sizeable gains is alluring. Of course, it’s very difficult to predict which way these shares are going to go. Sudden changes happen all the time with cheap stocks under $5, but some in...
Richland WA, July 29, 2019 (GLOBE NEWSWIRE) -- Vivos Inc . (OTCPINK: RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at the end of the stock ticker is removed 20 business days following the completion of the...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...